Transgenomic Q1 Revenues Slide 15 Percent | GenomeWeb

NEW YORK (GenomeWeb News) — Transgenomic said after the close of the market on Wednesday that its first quarter revenues declined 15 percent year over year.

For the three months ended March 31, the Omaha, Neb.-based molecular diagnostics firm logged total revenues of $6.3 million compared to $7.4 million in the prior-year period. Transgenomic attributed this decline primarily to lower sales in its Laboratory Services segment, reflecting higher-than-usual sales in Q1 2013 that had resulted from working down a backlog of Nuclear Mitome tests from 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.